115 results about "Myasthenias" patented technology

A Chinese medicine for treating the myophagism and myasthenia gravis caused by motor neuron diseases, prograssive myodystrophy and congenital myopathy is prepared from ginseng and epimedium. Its preparing process is also disclosed.

GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.

The invention relates to ginseng and antler muscle strengthening pills and a preparation method thereof, belonging to the field of natural Chinese herbal medicine. The type of drugs can regulate immune function, improve acetylcholine receptor function and strengthen muscle contraction ability. The drug formula is used for moistening lung, regulating qi, promoting production of fluid, strengthening spleen, strengthening kidney, replenishing essence, nourishing blood, soothing liver, strengthening muscle and increasing strength. The pills can effectively inhibit abnormal autoimmunity response and solve the acetylcholine transfer disorder. The pills have significant efficacy for myasthenia gravis.

The invention provides a method for determining content of various components in a Chinese medicinal composition freeze-dried injection. The Chinese medicinal freeze-dried injection comprises ginseng and epimedium herb which serve as raw materials and is clinically used for treating amyotrophy and myasthenia gravis which are caused by diseases such as motoneuron diseases (amyotrophic lateral sclerosis, progressive spinal muscular atrophy, progressive bulbar palsy and primary lateral sclerosis), progressive muscular dystrophy, congenital myopathy and the like. In the method, 15 active compounds in the Chinese medicinal freeze-dried injection are qualitatively and quantitatively analyzed simultaneously by a tandem mass spectrometry of a high performance liquid chromatography, and the method can be used for quality control of a product.

The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.

The invention provides a method for determining residual organic solvents in the freeze-dried injection of a traditional Chinese medicine composition. The raw materials of the freeze-dried injection of the Chinese medicine include ginseng and epimedium, which are clinically used for motor neuron diseases (amyotrophic lateral sclerosis, amyotrophic lateral sclerosis, spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis), progressive muscular dystrophy, congenital myopathy and other diseases caused by muscular atrophy and myasthenia gravis, the method of the present invention uses the top The residual amount of organic solvent can be determined by air chromatography, which can be used for the quality control of the product.

The invention provides a traditional Chinese medicinal composition freeze-drying injection and a preparation method thereof. The traditional Chinese medicament freeze-drying injection is prepared from raw materials comprising ginseng and epimedium herb by extraction and refinement of a modern process and then by a freeze-drying process. The traditional Chinese medicament preparation meets technical requirements of the State Food and Drug Administration (SFDA) on the traditional Chinese medicament injection and is clinically applied to treatment on amyotrophy and myasthenia gravis caused by diseases such as motor neuron diseases (amyotrophic lateral sclerosis, progressive spinal muscular atrophy, progressive bulbar palsy and primary lateral sclerosis), progressive myodystrophy, congenital myopathy and the like. The traditional Chinese medicament freeze-drying injection is administrated clinically through intravenous, intramuscular or acupoint injection.

The invention provides a Chinese medicinal composition for treating myasthenia gravis. The composition basically comprises astragalus root, bupleurum, desertliving cistanche, epimedium, Chinese date and schisandra. Meanwhile, the invention also provides a composition which has improved effect and is added with additional components. Proved by pharmaceutical effect experiments of the applicant andcompared with the prior art, the medicinal composition is simply prepared and has good treatment effect.

The invention discloses a lentiviral plasmid expression vector as well as a construction method and an application of the lentiviral plasmid expression vector. The lentiviral plasmid expression vector is pCDH-MCS-MuSK-GFP and the nucleotide sequence of the lentiviral plasmid expression vector is shown in SEQ ID NO. 2 in a sequence table. The invention further discloses an application of the lentiviral plasmid expression vector in construction of an anti-muscle-specific receptor tyrosine kinase antibody detection. According to the invention, a stable transfected cell line of MuSK is established by constructing a viral vector, a MuSK antibody is qualitatively and quantitatively detected clinically by an immunofluorescence staining method with relatively high sensitivity and specificity in combination with a flow cytometry, the detection results are more stable and manpower and time costs are greatly saved. The diagnosis and treatment levels of myasthenia gravis are greatly improved by the establishment of the project, the labor capacity and life quality of patients are improved and the lentiviral plasmid expression vector has significant social and economic benefits.

The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.

Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis.

The invention discloses an antigen-specific immature DC (dendritic cell) source exosome as well as preparation and application methods thereof. The maturity of a bone marrow derived dendritic cell (BMDC) is interfered by using microRNA-146a mimics, and then through detecting the expression of CD80, CD86 and MHC II molecules on the surface of the BMDC, a situation that the BMDC transfected by the microRNA-146a mimics has a capacity of resisting antigen mature stimulation is confirmed; and the transfected BMDC loads the pathogenic peptide fragment of MG, so that an antigen-specific immature DC is obtained, and an exosome secreted by the antigen-specific immature DC is the exosome provided by the invention. The exosome is used for treating myasthenia gravis, and can be further used for preparing medicines or preparations for treating myasthenia gravis; and the exosome has the advantages of simple preparation method, easiness for storage, strong stability, remarkable effect, strong specificity, small side effects, and the like, therefore, the exosome has a broad application prospect.

The invention discloses a traditional Chinese medicine combination for preparing medicine for treating myasthenia gravis. The combination has an immune reconstitution function, can be used for preparing medicine for treating diseases of immune systems and is especially suitable for treating myasthenia gravis.

The invention provides a medicament for treating myasthenia gravis and a preparation method thereof. The medicament for treating myasthenia gravis is prepared from Chinese ephedra, aconites, asarum, astragalus roots, ginseng, Chinese angelica roots, atractylodes rhizome, dodders, and the like. The medicament for treating myasthenia gravis promotes the circulation of qi and blood, nourishes muscles and has good effects on collecting yang, restoring qi and removing obstruction in channels. Clinical experiments prove that the medicament for treating myasthenia gravis can effectively treat myasthenia gravis.

Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis.

The invention relates to a lotus leaf extract, a monomer component and application thereof. An active monomer component of the extract is aporphine alkaloid and comprises 2-hydroxy-1-methoxy-aporphine, nuciferine and N-nornuciferine. The lotus leaf extract and the monomer component have good inhibition to acetylcholinesterase, and can be developed into medicaments for treating the diseases such as Alzheimer's disease, glaucoma, asthenic bulbar paralysis, intestinal obstruction and the like.

The invention provides a leg massage device for neurology nursing. The leg massage device comprises a stool body which is composed of a horizontal stool surface located at a top part position and stool columns fixedly and vertically installed on the periphery of the bottom part of the stool surface, and the leg massage device is characterized in that two first hinge seats are fixedly installed atthe bottom part of the stool surface of the stool body; two leg supports are arranged below one side of the stool surface; the upper end of each traction rod is connected with a corresponding third hinge seat in a hinged manner; and bandage fixing units are arranged at the front side and the rear side of the periphery of each leg support respectively. According to the invention, the strength of apatient is converted into power; blood circulation is promoted; meanwhile, the symptom of myasthenia of a bedridden patient can be avoided; the exercise function and the massage function are combined;the leg massage device is particularly suitable for being used by a neurology patient who still has a certain leg movement function but is not suitable for directly walking on the ground; and the stool body of the leg massage device can also be replaced by a chair, or the leg supports are directly installed on the edge of a bed in the same connection mode, so the use comfort of a patient is improved.

The invention provides compositions and methods for detecting or determining the severity of myasthenia gravis in a subject. The invention also provides compositions and methods for preventing or treating myasthenia gravis in a subject. In some embodiments, the compositions are peptides that bind to monoclonal antibodies that bind to the main immunogenic region of an acetylcholine receptor, and in some instances block pathogenic antibody combining sites. In other embodiments, the peptides further comprise an antibody heavy chain fragment. Kits for detecting or determining the severity of and preventing or treating myasthenia gravis are also provided.

Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

The invention discloses a cell slide for detecting an acetylcholine receptor autoantibody in human body fluid as well as a preparation method and application of the cell slide, and belongs to the technical field of biology. According to the scheme, the method comprises the following steps: co-transfecting each subunit of an acetylcholine receptor and a no-load plasmid according to a certain proportion, and then fixing, washing, terminating, washing and drying to prepare the cell slide for detecting the autoantibody of the acetylcholine receptor in human body fluid. Compared with a radioimmunoassay and an enzyme-linked immunosorbent assay, the method has higher sensitivity; compared with an immunofluorescence method reported in literatures in the prior art, the method has the advantage that the detection specificity is improved while the background is reduced. Therefore, from the perspective of research or as an auxiliary diagnosis means of the myasthenia gravis disease, the method has a good application prospect.

The present invention relates to atypical cannabinoids, i.e. ligands of the peripheral cannabinoid receptor CB2, and pharmaceutical compositions thereof comprising novel (+) α-pinene derivatives as active ingredients, which are useful in the prophylaxis of and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, type I diabetes, hepatitis, psoriasis and immune Associated disorders, including but not limited to tissue rejection in organ transplantation, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, including peripheral, visceral, neurological Sexual, inflammatory and associated pain, muscle spasms, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, nervous system disorders including stroke, migraine and cluster headaches, including Parkinson's disease, Neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, prion-related neurodegeneration, CNS poisoning, and certain types of cancer.

The invention discloses a special wheelchair convenient for a myasthenia person to sit and walk. The special wheelchair comprises a wheelchair main body, wherein a seat plate supporting frame is arranged at the upper end of the wheelchair main body; a leg supporting frame is movably arranged at one end of the seat plate supporting frame through a rotating shaft; a first electric push rod is arranged between the seat plate supporting frame and the leg supporting frame; one end of the first electric push rod is connected with the seat plate supporting frame, and the other end of the first electric push rod is connected with the leg supporting frame; a second electric push rod is arranged between the wheelchair main body and the seat plate supporting frame; one end of the second electric pushrod is connected with the wheelchair main body, and the other end of the second electric push rod is connected with the seat plate supporting frame; and a backrest armrest frame is arranged at the other end of the seat plate supporting frame. According to the special wheelchair convenient for the myasthenia person to sit and walk, the health problem caused by long-term bed rest or fixed posturesof myasthenia persons is solved, and meanwhile, the living quality of the myasthenia persons is improved.

The invention discloses a pure Chinese medical composition for tonifying the spleen and eliminating losses and a preparation method thereof. The pure Chinese medical composition comprises the following raw components by weight ratio: 60 parts of astragalus mongholicus, 18 parts of codonopsis pilosula, 15 parts of rhizoma atractylodis, 3 parts of licorice, 10 parts of codonopsis pilosula, 3 parts of pericarpium citri reticulatae, 10 parts of dendrobe, 10 parts of cimicifugae foetidae, 30 parts of coix semen, 20 parts of herba epimedii and 10 parts of fritillaria thunbergii. The pure Chinese medical composition is a pure Chinese medical composition oral liquid preparation, has effects of tonifying the spleen and eliminating losses, and is used for treatment of myasthenia gravis. Compared with the existing similar products in the market, the pure Chinese medical composition has the advantages of low dosage, good taste, convenience in taking, rapider absorption, high bioavailability, higher efficacy, stable quality, simple production process and the like.

The invention discloses an anti-C5 full-human derived single-chain antibody C5B3 and application thereof. The anti-C5 full-human derived single-chain antibody C5B3 has a DNA (Deoxyribonucleic Acid) sequence as shown in SEQ ID NO:1. By adopting the antibody, formation of a membrane attacking composition in an inflammation reaction process can be remarkably inhibited, so that damage caused in the inflammation reaction process can be reduced. The invention further discloses application of the anti-C5 full-human derived single-chain antibody C5B3 in preparing medicines for treating autoimmune diseases such as ophthalmoneuromyelitis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis and / or inflammation and diseases with related symptoms caused by paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndrome (AHU) and trauma.

The present disclosure provides an siRNA capable of inhibiting expression of a complement protein 5(C5) gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is an independent modified or unmodified nucleotide. The siRNA comprises a sense strand and an antisense strand. The sense strand comprises a nucleotide sequence I, and the nucleotide sequence I has the same length and no more than three nucleotide differences from a nucleotide sequence shown in SEQ ID NO: 1. The antisense strand comprises a nucleotide sequence II, and the nucleotide sequence II has the same length and no more than three nucleotide differences from a nucleotide sequence shown in SEQ ID NO: 2. The siRNA, the pharmaceutical composition and the conjugate thereof provided by the present disclosure can effectively treat and / or prevent complement-mediated related diseases, such as myasthenia gravis (MG).

The invention discloses a seat sliding adjusting mechanism-based medical leg exerciser, and belongs to the technical field of medical rehabilitation equipment. The seat sliding adjusting mechanism-based medical leg exerciser comprises a base; a stand column is connected to the top of the base; a seat main body is connected to the end, away from the base, of the stand column; grooves are dug in the outer wall of the base; a sliding block is slidably connected to the inner wall of each groove; a pedal assembly is connected to the top of each sliding block; side plates are connected to the top wall of the base; a first rotating rod is connected to the inner wall of each side plate; and a swing rod is connected to the outer wall of each first rotating rod. The medical leg exerciser is suitable for leg bending and stretching exercise of myasthenia or unconscious patients; legs are supported through auxiliary supporting plates during exercise, thus avoiding secondary injury of the legs caused by nonstandard placement due to leg weakness during exercise rehabilitation exercise of the legs of the patients, and by massaging the legs are massaged, blood circulation is promoted, and the exercise effect is enhanced.

The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90α), and heat-shock protein 90, beta isoform (hsp90β). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.

The invention discloses new application of artemisinin and derivatives thereof. The inventor finds that the artemisinin and the artemisinin derivatives significantly improve the activity of choline acetyltransferase in HT22 hippocampal neuronal cells and primary culture neurons, improve the plasticity of cholinergic neuronal synapses, and reduce the apoptosis of cholinergic neuronal cells, so that the function of a cholinergic nervous system is improved. In an animal model, the artemisinin and the derivatives thereof are also found to be capable of improving the activity of choline acetyltransferase and improving learning and memory. In addition, the artemisinin medicine also regulates / improves the activity of choline acetyltransferase of various cell tissues of animals of various ages, which indicates that the artemisinin medicine also can be used for treating other cholinergic insufficiency (abnormality) related diseases. Comprising but not limited to prevention and treatment of aging, postoperative cognitive impairment, dementia, schizophrenia, Huntington's disease, autism, myasthenia gravis, hyperactivity, respiratory distress syndrome and immune dysfunction of the organism.

The invention discloses a clinical multifunctional training massage device for neurology department. The device includes a base, the top of which is fixedly connected with a U-shaped frame. The left and right sides of the U-shaped frame are all provided with lapping holes. The left side of the U-shaped frame near the top is fixedly connected with a motor. The right end of the output shaft on the motor is fixedly connected with a reciprocating screw. The surface tube of the reciprocating screw passes through the left side of the U-shaped frame and rotates on the U-shaped frame in a limited manner. According to the invention, through the cooperation and use of the above structures, the following problems are solved: in the actual use process, due to the insufficiency of safety performance ofa traditional load-bearing pull ring, It is easy to cause damage to the arm joints of patients, and the muscles on the arms of the general myasthenia gravis patients are difficult to adapt to the training of the weight-bearing pull ring during the initial massage training, and the nursing staff are extremely prone to fatigue after a long period of auxiliary beating, resulting in poor beating effect and poor recovery effect of the patients, and being difficult to meet the actual needs of the patients.

The invention discloses a myasthenia finger function rehabilitation training system based on a multi-sensor data glove. The myasthenia finger function rehabilitation training system comprises a sensor data communication module, a rehabilitation training development module and a data management storage module. A user transmits hand information to the system in real time by wearing a data glove, wherein the data glove comprises three sensors, namely a stretchable and bendable sensor for monitoring finger movement states, an inertial sensor for capturing palm space movement states and a flexible pressure sensor for detecting hand grasping force; the intelligent rehabilitation training system can be autonomously used by a user, qualitative training data of the user is changed into quantitative training data, training actions of the user are visualized, and the training data of the user are displayed and stored in real time, so that rehabilitation doctors can propose feedback suggestions for rehabilitation training of the user, and the rehabilitation training efficiency is improved. Various sensor data are connected with a virtual hand by using a virtual reality technology, and a user is helped to perform autonomous rehabilitation training through an auxiliary training game.